The amyloid hypothesis—the idea that Alzheimer’s is caused by clumps of proteins known as beta-amyloid—remains unproven. But scientists are holding out hope that monoclonal…
Eisai’s investigational Alzheimer’s drug lecanemab appeared to erase amyloid plaques in 4/5 of trial participants and slow cognitive decline for people with early-stage Alzheimer’s…
Data on Cassava Sciences’ Alzheimer’s drug candidate, simufilam, found it was not only safe, but modified disease biomarkers at six months, and improved cognition…
New research takes one of the most widespread and fundamental theories about what causes Alzheimer’s and turns it on its head: Now some scientists…
Will Medicare cover Alzheimer’s drugs like Aduhelm? That decision-making process is underway. This week, the U.S. government embarked on the formal review process to…
The FDA will hasten the review of two more new Alzheimer’s drug candidates, Eli Lilly & Co.’s donanemab and Biogen and Eisai’s lecanemab. Today,…
Looking for answers about Alzheimer’s treatment Aduhelm (generic name aducanumab)? Here’s a primer on what it is, what it does, and more, according to…